Kangtai Bio

Immunotherapy in China: A Rising Star in the Field of Cancer Treatment

Immunotherapy is emerging as a powerful weapon in fighting cancer by restarting and maintaining the cancer-immunity cycle to identify, control and eliminate tumor cells rather than killing them directly.

Gene Synthesis Provider Tsingke Biotechnology Nets Over CNY 400 Mn in Series B

Tsingke, a national high-tech enterprise in synthetic biology, raised CNY 400 Mn in Series B only 1 year after its completion of Series A in 2021

China to Enforce New Law on Online Sale of Medicinal Products

As the new law on online drug sale of medicinal products comes into effect, stricter supervision and administration of online medicinal products selling will be conducted.

15 Companies to Watch in November 2022-Healthcare

Editor's note: We at EqualOcean tracked the major funding rounds or industry events that took place in China's healthcare space in November 2022. And the following is a list of deals that we have selected for you, based on a number of criteria, including the funding amount, the financial backers, and the segments in which the startups operate.

Pre-clinical CRO ZHSK Lab Nets Over CNY 100 Mn in Series B

ZSHK, a pre-clinical Contract Research Organization (“Preclinical CRO”), raised funds from AZ-CICC and its existing investor Jishi Capital to enhance international deployment and key resources construction